(Q38396089)

2 September 2017

1 reference

title

Cancer chemotherapy in infants and children (English)

1 reference

2 September 2017

Bleyer WA

1

1 reference

2 September 2017

publication date

1 June 1985

1 reference

Pediatric Clinics of North America

2 September 2017

published in

1 reference

2 September 2017

volume

32

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

557-574

1 reference

Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Clinical pharmacokinetics of commonly used anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Clinical pharmacology of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Rapid high-pressure liquid chromatographic determination of methotrexate and its metabolites 7-hydroxymethotrexate and 2,4-diamino-N(10)-methylpteroic acid in biological fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Cyclophosphamide cystitis—Identification of acrolein as the causative agent

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Bleomycin pulmonary toxicity: Its relationship to renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Decreased half life of cyclophosphamide in patients under continual treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Low-dose methotrexate kinetics in arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

The relative tolerance of children and adults to anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Clinical pharmacology of the 6-thiopurines

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Clinical Pharmacokinetics of Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

The bioavailability of oral intermediate-dose methotrexate. Effect of dose subdivision, formulation, and timing in the chemotherapy cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Clinical kinetics on intact cisplatin and some related species

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Effect of hepatic irradiation on the toxicity and pharmacokinetics of adriamycin in children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Intravenous vincristine infusion: Phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Central nervous system toxicity of high-dose systemic cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Cancer treatment by methotrexate: rational use following pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Clinical implications of cisplatin pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Implantable devices for chronic access and drug delivery to the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Cisplatin (cis-diamminedichloroplatinum II)

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Sequential changes in platelet function and coagulation in leukemic children treated with L-asparaginase, prednisone, and vincristine

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Clinical pharmacology of intermediate-dose oral methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Clinical pharmacokinetics of methotrexate in children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Vincristine infusion. A phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Cis-platinum: a new anticancer agent

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Life-threatening neuropathy and hepatotoxicity in infants during induction therapy for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934824-6

7 January 2021

10.1016/S0031-3955(16)34824-6

Identifiers

DOI

0 references

1 reference